Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 May 15;90(10):4586–4590. doi: 10.1073/pnas.90.10.4586

The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

T Tanaka 1, J Kameoka 1, A Yaron 1, S F Schlossman 1, C Morimoto 1
PMCID: PMC46557  PMID: 7685106

Abstract

T cells have been shown to express CD26, a known ectoenzyme with dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) activity in its extracellular domain. CD26 can also deliver a second costimulatory signal and contribute to T-cell activation. In an earlier study, we established CD26-transfected Jurkat T-cell lines and demonstrated that monoclonal antibody-mediated crosslinking of CD26 and CD3 induced interleukin 2 (IL-2) production. To determine the contribution of DPPIV enzymatic activity to the costimulatory activity of CD26, human CD26 cDNA was mutated so that active-site serine was replaced by alanine. The mutant CD26 antigen lacked DPPIV enzyme activity but still retained reactivity with three anti-CD26 monoclonal antibodies directed against distinct epitopes of CD26. After stimulation with a combination of anti-CD26 and anti-CD3 antibodies, wild-type CD26 (DPPIV+)-transfected Jurkat cells produced substantially more IL-2 than did mutant CD26 (DPPIV-) or CD26- control transfectants. Nevertheless, the mutant CD26-transfected cells still produced significantly more IL-2 than did CD26- control transfectants. These results suggest that DPPIV activity plays an important but not absolute role in the co-stimulatory activity of CD26 in this system. We also found that wild-type CD26 (DPPIV+) transfectants produced more IL-2 than mutant CD26 (DPPIV-)-transfected cells or CD26- control transfectants when triggered by stimuli not involving CD26, such as anti-CD3 and phorbol ester. These results suggest that the DPPIV activity of CD26 functions to augment the cellular responses of CD26-transfected Jurkat cells to external stimuli mediated by CD26 and/or the CD3/T-cell receptor complex, thus enhancing IL-2 production.

Full text

PDF
4586

Images in this article

4588Fig. 2
on p.4588

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brenner S. The molecular evolution of genes and proteins: a tale of two serines. Nature. 1988 Aug 11;334(6182):528–530. doi: 10.1038/334528a0. [DOI] [PubMed] [Google Scholar]
  2. Dang N. H., Hafler D. A., Schlossman S. F., Breitmeyer J. B. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. Cell Immunol. 1990 Jan;125(1):42–57. doi: 10.1016/0008-8749(90)90061-u. [DOI] [PubMed] [Google Scholar]
  3. Dang N. H., Torimoto Y., Deusch K., Schlossman S. F., Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol. 1990 Jun 1;144(11):4092–4100. [PubMed] [Google Scholar]
  4. Dang N. H., Torimoto Y., Sugita K., Daley J. F., Schow P., Prado C., Schlossman S. F., Morimoto C. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol. 1990 Dec 15;145(12):3963–3971. [PubMed] [Google Scholar]
  5. De Meester I., Vanhoof G., Hendriks D., Demuth H. U., Yaron A., Scharpé S. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin Chim Acta. 1992 Sep 15;210(1-2):23–34. doi: 10.1016/0009-8981(92)90042-o. [DOI] [PubMed] [Google Scholar]
  6. Fleischer B. A novel pathway of human T cell activation via a 103 kD T cell activation antigen. J Immunol. 1987 Mar 1;138(5):1346–1350. [PubMed] [Google Scholar]
  7. Flentke G. R., Munoz E., Huber B. T., Plaut A. G., Kettner C. A., Bachovchin W. W. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1556–1559. doi: 10.1073/pnas.88.4.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fox D. A., Hussey R. E., Fitzgerald K. A., Acuto O., Poole C., Palley L., Daley J. F., Schlossman S. F., Reinherz E. L. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol. 1984 Sep;133(3):1250–1256. [PubMed] [Google Scholar]
  9. Geppert T. D., Davis L. S., Gur H., Wacholtz M. C., Lipsky P. E. Accessory cell signals involved in T-cell activation. Immunol Rev. 1990 Oct;117:5–66. doi: 10.1111/j.1600-065x.1990.tb00566.x. [DOI] [PubMed] [Google Scholar]
  10. Hafler D. A., Chofflon M., Benjamin D., Dang N. H., Breitmeyer J. Mechanisms of immune memory. T cell activation and CD3 phosphorylation correlates with Ta1 (CDw26) expression. J Immunol. 1989 Apr 15;142(8):2590–2596. [PubMed] [Google Scholar]
  11. Hegen M., Niedobitek G., Klein C. E., Stein H., Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol. 1990 Apr 15;144(8):2908–2914. [PubMed] [Google Scholar]
  12. Heike M., Möbius U., Knuth A., Meuer S., Meyer zum Büschenfelde K. H. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol. 1988 Dec;74(3):431–434. [PMC free article] [PubMed] [Google Scholar]
  13. Kenny A. J., Booth A. G., George S. G., Ingram J., Kershaw D., Wood E. J., Young A. R. Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem J. 1976 Jul 1;157(1):169–182. doi: 10.1042/bj1570169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kunkel T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488–492. doi: 10.1073/pnas.82.2.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kunkel T. A., Roberts J. D., Zakour R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
  16. Masuyama J., Berman J. S., Cruikshank W. W., Morimoto C., Center D. M. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol. 1992 Mar 1;148(5):1367–1374. [PubMed] [Google Scholar]
  17. Mead D. A., Szczesna-Skorupa E., Kemper B. Single-stranded DNA 'blue' T7 promoter plasmids: a versatile tandem promoter system for cloning and protein engineering. Protein Eng. 1986 Oct-Nov;1(1):67–74. doi: 10.1093/protein/1.1.67. [DOI] [PubMed] [Google Scholar]
  18. Morimoto C., Torimoto Y., Levinson G., Rudd C. E., Schrieber M., Dang N. H., Letvin N. L., Schlossman S. F. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol. 1989 Dec 1;143(11):3430–3439. [PubMed] [Google Scholar]
  19. Nagatsu T., Hino M., Fuyamada H., Hayakawa T., Sakakibara S. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem. 1976 Aug;74(2):466–476. doi: 10.1016/0003-2697(76)90227-x. [DOI] [PubMed] [Google Scholar]
  20. Ogata S., Misumi Y., Tsuji E., Takami N., Oda K., Ikehara Y. Identification of the active site residues in dipeptidyl peptidase IV by affinity labeling and site-directed mutagenesis. Biochemistry. 1992 Mar 10;31(9):2582–2587. doi: 10.1021/bi00124a019. [DOI] [PubMed] [Google Scholar]
  21. Schön E., Demuth H. U., Eichmann E., Horst H. J., Körner I. J., Kopp J., Mattern T., Neubert K., Noll F., Ulmer A. J. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol. 1989 Feb;29(2):127–132. doi: 10.1111/j.1365-3083.1989.tb01108.x. [DOI] [PubMed] [Google Scholar]
  22. Schön E., Jahn S., Kiessig S. T., Demuth H. U., Neubert K., Barth A., Von Baehr R., Ansorge S. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol. 1987 Dec;17(12):1821–1826. doi: 10.1002/eji.1830171222. [DOI] [PubMed] [Google Scholar]
  23. Siekierka J. J., Staruch M. J., Hung S. H., Sigal N. H. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol. 1989 Sep 1;143(5):1580–1583. [PubMed] [Google Scholar]
  24. Streuli M., Hall L. R., Saga Y., Schlossman S. F., Saito H. Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med. 1987 Nov 1;166(5):1548–1566. doi: 10.1084/jem.166.5.1548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tanaka T., Camerini D., Seed B., Torimoto Y., Dang N. H., Kameoka J., Dahlberg H. N., Schlossman S. F., Morimoto C. Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992 Jul 15;149(2):481–486. [PubMed] [Google Scholar]
  26. Torimoto Y., Dang N. H., Tanaka T., Prado C., Schlossman S. F., Morimoto C. Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol Immunol. 1992 Feb;29(2):183–192. doi: 10.1016/0161-5890(92)90099-j. [DOI] [PubMed] [Google Scholar]
  27. Torimoto Y., Dang N. H., Vivier E., Tanaka T., Schlossman S. F., Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 1991 Oct 15;147(8):2514–2517. [PubMed] [Google Scholar]
  28. Ulmer A. J., Mattern T., Feller A. C., Heymann E., Flad H. D. CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7. Scand J Immunol. 1990 Apr;31(4):429–435. doi: 10.1111/j.1365-3083.1990.tb02789.x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES